Summary: Early diagnosis of invasive pulmonary aspergillosis (IPA) remains difficult due to the variable performance of the tests used. We compared the performance characteristics of Aspergillus lateral flow device (LFD) in bronchoalveolar lavage (BAL) vs. BAL‐galactomannan (GM), for the diagnosis of IPA. 311 BAL specimens were prospectively collected from patients who underwent bronchoscopy from January to May 2013. Patients at risk for IPA were divided into haematological malignancy (HEM) and non‐HEM groups: solid organ transplants (SOT) (lung transplant (LT) and non‐LT SOT); chronic steroid use (CSU); solid tumour (STU) and others. We identified 96 patients at risk for IPA; 89 patients (93%) were in the non‐HEM groups: SOT 57 (LT, 46, non‐LT SOT, 11); CSU 21; STU 6, other 5. Only three patients met criteria for IA (two probable; one possible). Overall sensitivity (SS) was 66% for both and specificity (SP) was 94% vs. 52% for LFD and GM respectively. LFD and GM performance was similar in the HEM group (SS 100% for both and SP 83% vs. 100% respectively). LFD performance was better than GM among non‐HEM SOT patients (P = 0.02). Most false‐positive GM results occurred in the SOT group (50.8%), especially among LT patients (56.5%). LFD performance was superior with an overall SP of 95.6% in SOT (P < 0.002) and 97% in LT patients (P = 0.0008). LFD is a rapid and simple test that can be performed on BAL to rule out IPA.
Aspergillus; lateral flow device; diagnosis; brochoalveolar lavage
Invasive pulmonary aspergillosis (IPA) is an important cause of morbidity and mortality among immunocompromised patients.[
The diagnosis of IPA remains challenging given the lack of a single gold standard test. Current diagnosis of IPA is based on host factors and clinical, radiological and microbiological criteria which are neither sensitive nor specific.[
New strategies for diagnosis and management of IPA include the use of non‐invasive biomarkers (i.e. galactomannan (GM) and 1,3 beta‐d‐glucan). The role of serum and bronchoalveolar lavage (BAL) GM for the diagnosis of IPA has been best established in patients with haematological malignancies.[
Aspergillus immuno‐chromatographic lateral flow device (LFD) is a novel technique that uses an Aspergillus – specific monoclonal antibody (mAb JF5).[
We sought to determine the performance characteristics of the LFD using BAL for the diagnosis of IPA in patients at risk of invasive fungal infection (IFI) who underwent bronchoscopy at the Henry Ford Health System. Second, we compared the performance of BAL‐LFD to that of BAL‐GM.
We prospectively collected aliquots of all BAL specimens obtained from bronchoscopies performed at HFHS from January 2013 to May 2013. These BAL aliquots were stored at −20 °C for GM and LFD testing. All BAL specimens were stored at room temperature for up to 2 h or at 4 °C for up to 24 h before being stored at −20 °C. Specimens remained frozen up to 6 months before GM and LFD testing was performed. Clinical information regarding risk factors and diagnostic criteria for IPA was collected by retrospective chart review. Patients were classified as risk for IPA according to the current European Organization for Research and Treatment of Cancer /Mycoses Study Group (EORTC/MSG) guidelines for IFI.[
Retrospective Aspergillus GM (Platelia
The Aspergillus‐LFD was performed on stored BAL fluid from all patients included in the study. The BAL‐LFD testing was performed in the Infectious Disease Research Laboratory at HFHS, following the manufacturer's method process (Isca Diagnostics, Truro, Cornwall, UK). Results of BAL‐LFD testing were read at 10 min after applying the fluid to the LFD sample well.[
We compared the diagnostic performance of LFD and GM in BAL fluid from patients at risk for IPA. The BAL‐LFD results were blindly analysed by one of the investigators in this study.
Fisher's exact test was used to test the null hypothesis that GM and LFD have the same specificity.
We prospectively collected BAL samples from 311 patients. Of these, 96 patients were identified at risk for IPA. The enrolment and distribution of patients is summarised in Fig. [NaN] . Mean patient age was 61 years (range: 35–81), 59 were female. Most patients, 89 of 96 (93%) were in the non‐HEM groups: 57 SOT patients (LT: 46 patients, non‐LT SOT: 11 patients), chronic steroid use: 21 patients, solid tumour: six patients and other: five patients. Only three patients in the study met criteria for IPA (2 probable; 1 possible IPA). The two patients with probable IPA had compatible clinical and radiographical findings and a positive BAL culture with Aspergillus species. One of these two cases was a haematological cancer patient with positive BAL‐LFD and positive serum and BAL‐GM (OD index 0.86 and 7.7 respectively). The patient was started on treatment with voriconazole but died 6 days later. The other patient had HIV infection with a CD4 cell count of 110/mm
The overall sensitivity and specificity of BAL‐GM for IPA was 66% and 52% respectively. Sensitivity and specificity of BAL‐LFD were 66% and 94% respectively. Test performance was similar for BAL‐LFD and BAL‐GM in the HEM group (sensitivity 100% for both and specificity 83% vs. 100% respectively). However, BAL‐LFD showed a better performance than BAL‐GM in the non‐HEM groups, particularly in the SOT group (P = 0.002) (Table [NaN] ). Forty‐four of 96 (45%) BAL‐GM showed false‐positive results, using a BAL‐GM cut‐off ≥0.5 OD index. False‐positive BAL‐GM were more frequent in the SOT group (29/57 patients; 50.8%), especially among LT recipients (26/46 patients; 56.5%). False‐positive BAL‐GM results were associated with lower OD index values (average: 1.49; range: 0.5–7.18) compared to true positive results (average: 5.86; range 4.02–7.7). Increasing the BAL‐GM cut‐off to ≥1.0 OD index improved the specificity compared to BAL‐GM cut‐off at ≥0.5 OD index (74% vs. 52%). Conversely, BAL‐LFD performance was superior with an overall specificity of 95.6%, particularly among SOT and LT recipients (P < 0.002 and 0.0008 respectively).
Specificity of Aspergillus lateral flow device test and galactomannan in bronchoalveolar lavage fluid by patient groups
Group at risk (n = 96) GM (≥0.5 ODI) LFD P value GM (≥1.0 ODI) LFD P value HEM group (n = 7) 0.66 1.00 0.45 0.83 1.00 1.0 Non‐HEM group (n = 89) SOT group (n = 57) 0.49 0.96 <0.000001 0.75 0.96 <0.0021 Lung TX (n = 46) 0.43 0.97 <0.0001 0.71 0.97 0.0008 Non‐lung (n = 11) 0.72 0.90 0.59 0.90 0.90 1.0 Solid tumour (n = 6) 0.16 1.00 0.02 0.66 1.00 0.45 Chronic steroid use (n = 21) 0.71 0.90 0.24 0.76 0.90 0.40 Other (n = 5) 0.30 1.00 0.4 0.33 1.00 0.4
1 GM, galactomannan; LFD, lateral flow device; ODI, optic density index; HEM group, haematological malignancy and peripheral stem cell transplant group; SOT group, solid organ transplant recipients, further divided into lung transplant (lung Tx) group and non‐lung groups).
Seven patients had positive BAL‐LFD test results. Two of them met criteria of IPA (true positive results) and were described above. False‐positive BAL‐LFD results were observed in five patients from the non‐Hem group (SOT group, two; chronic steroid use, two; solid tumour, one). Four of these five patients also tested falsely positive for BAL‐GM. The BAL fluid fungal cultures from all five patients were negative. Results are summarised in Table [NaN] .
Summary of seven patients with positive bronchoalveolar lateral flow device test results
Risk factor IPA BAL‐LFD result BAL‐GM result BAL culture result SOT (non‐lung) No‐IPA False positive False positive (7.18 ODI) No growth Chronic steroid use No‐IPA False positive False positive (1.67 ODI) No growth Chronic steroid use No IPA False positive False positive (5.0 ODI) No growth HEM group Probable IPA True positive True positive (7.7 ODI) Aspergillus fumigatus Solid tumour No IPA False positive False positive (0.94 ODI) No growth SOT (lung transplant) No IPA False Positive True negative (0.27 ODI) No growth Other (critically ill patient) Possible IPA True Positive True positive (4.02 ODI) Not available
2 BAL, bronchoalveolar lavage; GM, galactomannan; HEM group, haematological malignancy and peripheral stem cell transplant group; IPA, invasive pulmonary aspergillosis; LFD, lateral flow device; ODI, optic density index; SOT group, solid organ transplant recipients, further divided into lung transplant non‐lung groups).
Eight patients grew mould from fungal cultures of BAL fluid (Aspergillus species four, other moulds: four). Among the four patients with Aspergillus species in BAL fungal culture, only two patients met criteria of probable IPA by EORTC/MSG definition. These two patients were described above. One of them tested positive for BAL‐LFD (true positive) and BAL‐GM (7.7 OD index) (true positive), whereas the other patient tested negative for BAL‐LFD and GM (false negative). The remaining two patients with Aspergillus species in BAL fungal culture did not meet criteria for IPA. Both patients had a positive BAL‐GM at 0.83 and 1.35 OD index, respectively (false positive), and both had negative BAL‐LFD (true negative).
We also evaluated cross‐reactivity of BAL‐GM and BAL‐LFD with other moulds growing from BAL cultures of 4 LT recipients. Fungal BAL cultures in these patients yielded Fusarium sp, Exophiala jenselmei, Emmonsia sp, and Penicillium sp respectively. None of these patients met EORCT/MSG definition criteria for IPA and isolated moulds were regarded as contaminant. The results of BAL‐LFD were negative in all four patients (true negative), whereas BAL‐GM results were positive in two of these four patients (false positive). Cross‐reaction of BAL‐GM was observed with Fusarium sp and Emmonsia sp.
We evaluated the diagnostic performance of the novel Aspergillus LFD and GM done on BAL obtained from a large and heterogeneous group of patients at high risk for IPA. In our study, the overall performance of BAL‐LFD for the diagnosis of IPA was superior to BAL‐GM, particularly among patients in the non‐Hem group. Indeed, specificity of BAL‐LFD was higher in the SOT group, especially among LT patients. These findings confirm those of Willinger et al.[
Classic diagnostic criteria for the diagnosis of IPA are difficult to apply in the SOT patients.[
False‐positive BAL‐GM test results in SOT particularly among LT recipients are not uncommon.[
In our study, no cross‐reactivity was observed with BAL‐LFD. Five BAL‐LFD results were falsely positive, but the cause for false‐positive results could not be determined. False‐positive test results and potential cross‐reactivity of BAL‐LFD with other fungal antigens have been described. Initial in vitro studies showed that the MAb JF5 used in the LFD cross‐reacted with antigens from Paecilomyces variotti and non‐pathogenic Penicillium species.[
One study reports on a patient (1 of 47) with false‐negative BAL‐LFD in a patient with diagnosis of probable IPA in a kidney transplant recipient, with a BAL‐GM of 24.9 OD index and negative BAL culture.[
Our findings suggest that Aspergillus LFD in BAL fluid may be considered as a valuable aid to rule out IPA in high‐risk population, especially in LT recipients that have a high prevalence of airway colonisation with Aspergillus species. Indeed, having a rapid and accurate test to help rule out the presence of IPA in these patients would be important to prevent overtreatment with broad‐spectrum antifungal agents and the potential drug–drug interactions and toxicities associated with these agents. The four studies evaluating the performance of BAL‐LFD for the diagnosis of IPA vs. no‐IPA are summarised in Table [NaN] .
Summary of studies on the performance of lateral flow device testing in bronchoalveolar fluid of patients at risk of invasive pulmonary aspergillosis
37 BAL from patients at risk of IPA [HM, 27; SOT, 10 (LT, 5)] IPA 21 patients: probable (12), possible (9) Indication for BAL testing: clinical suspicion of IPA BAL‐LFD: SS 100%; SP 81%; PPV 71%; NPV 100% Cross‐reaction: Penicillium sp (1) False‐negative BAL‐LFD results: none False‐negative BAL‐GM results: five (all five patients met criteria of possible IPA, had positive BAL‐LFD and were on anti‐mould prophylaxis) 67 BAL from patients at risk for IPA (HM, 43; SOT, 4; CLD, 12; ICU, 4; AIDS, 2; other, 2) IPA 26 patients: proven (3), probable (7), possible (16) Indication for BAL testing: clinical suspicion of IPA 51 of 67 had all 5 test results available BAL‐GM ODI ≥0.5: SS 80%; SP 98%; PPV 89%; NPV 95% BAL‐GM ODI ≥1.0: SS 70%; SP 98%; PPV 88%; NPV 93%; BAL fungal culture: SS 50%; SP 95%; PPV 71%; NPV 89% BAL‐BDG: SS 80%; SP 76%; PPV 44%; NPV 94% BAL Aspergillus PCR: SS 70%; SP 100%; PPV 100%; NPV 93% BAL‐LFD: SS 80%; SP 95%; PPV 80%; NPV 95% 47 BAL from SOT patients (LT, 26). IPA 22 patients: probable or proven (11) and possible (11) Indication for BAL testing: clinical suspicion of IPA BAL‐LFD: SS 91%; SP 83%; PPV 63%; NPV 97% False‐positive results (6/25): Cross‐reactivity with Penicillium sp (1), LT patient with Aspergillus sp cultured from BAL (3), unknown (2) False‐negative results (1/22) 96 BAL from patients at risk of IPA {HM, 7; non‐HM, 89 [SOT 57, (LT: 46; non‐LT SOT: 11), CSU 21, STU 6, other 5]} IPA 3 patients (probable 2, possible 1) Indication for BAL testing: medical necessity including clinical suspicion of IPA BAL‐LFD: SS 66%; SP 94% BAL‐GM ODI >0.5: SS 66%; SP 52% BAL‐GM ODI ≥1.0: SS 66%; SP 74% False‐positive results BAL‐LFD: 5; cross‐reaction: none False‐negative results BAL‐LFD: 1 False‐positive BAL‐GM ≥0.5: 44 (LT, 26 patients) Serum and BAL Aspergillus GM were not used as mycological criterion for the diagnosis of IPA. Analysis was limited due to small number of patients with IPAReferences Objective Study patients Test performance for the diagnosis of IPA vs. no‐IPA Comments Hoenigl et al. 11 Evaluation of BAL‐LFD vs. BAL‐GM (cut‐off ≥1.0 ODI) and BAL fungal culture for the diagnosis of probable IPA BAL Aspergillus GM and fungal culture were used as mycological criterion for the diagnosis of IPA Hoenigl et al. 12 Evaluation of BAL‐GM, BAL fungal culture, BAL‐BDG, BAL‐LFD and BAL Aspergillus PCR assay for the diagnosis of IPA Cases of possible IPA were excluded from the analysis. Cross‐reactivity, false positive and false‐negative test results were not discussed Willinger et al. 13 Evaluation of BAL‐LFD vs. BAL‐GM (cut‐off >1.0 ODI) and BAL culture for the diagnosis of proven or probable IPA. BAL‐GM and fungal culture were used as mycological criterion for the diagnosis of IPA. Cases of possible IPA were excluded Miceli et al. (this study) Evaluation of BAL‐GM (cut‐off ≥0.5 and ≥1.0) vs. BAL‐LFD the diagnosis of proven, probable, or possible IPA in patients at risk.
3 AIDS, acquired immune deficiency syndrome; BAL, bronchoalveolar lavage; BDG, beta‐D‐glucan; CLD, chronic lung disease; CSU, chronic steroid use; GM, galactomannan; HM, haematological malignancy and peripheral stem cell transplant recipients; ICU, intensive care unit patients; IPA, invasive pulmonary aspergillosis; LFD, lateral flow device; LT, lung transplant recipients; NPV, negative predictive value; ODI, optic density index; PPV, positive predictive value; SOT, solid organ transplant recipients; SP, specificity; SS, sensitivity; STU, solid tumour.
Our study has limitations that should be acknowledged, including the small sample size, with only three cases of probable/possible IPA. Another important limitation is that classic EORTC/MSG definition criteria for the diagnosis of IA are difficult to apply in non‐neutropenic patients, particularly SOT recipients which represent the largest group in our study. Furthermore, we used very inclusive eligibility criteria, we have included all patients at risk for IPA who underwent bronchoscopy and had BAL fluid obtained regardless the indication for this procedure (e.g.: surveillance bronchoscopy following LT, mucus plug removal, suspected pneumonia, aspiration, etc.). This means that most of our patients did not undergo bronchoscopy for suspected IPA. Thus, it is not surprising that only three patients in our cohort met criteria of possible/probable IPA. Consequently, our statistical analysis was limited to specificity. More patients with probable/proven IPA (true positive) should be included in future studies to evaluate sensitivity of the test. Only after evaluating both sensitivity and specificity would we will be able to make a more definitive comparison of the diagnostic performance of both methods (BAL‐LFD vs. BAL‐GM).
Finally, retrospective BAL‐GM testing should be mentioned as a potential limitation of this study. However, a recent study comparing prospective real‐time vs. retrospective BAL‐GM testing showed minimal change in the BAL‐GM OD index when BAL specimens were stored at −20 °C for up to 11 months.[
In summary, our data demonstrate that BAL‐LFD is a promising tool for the diagnosis of IPA. Aspergillus LFD is a rapid, simple, potential point‐of‐care and inexpensive test performed on BAL that could help to rule out IPA in high‐risk population, particularly LT recipients. More studies are needed to further determine the role of BAL‐LFD in patients with suspected diagnosis of IPA.
We thank Ann Tyson, Patrice McFarland, Teresa Wiegand and Sharon Skorupski for all their help and support in this project.
No funding was obtained for this study. The Aspergillus LFD tests used in this study were provided by Dr. Christopher Thornton, University of Exeter. Dr. Thornton is the inventor of the Aspergillus LFD test. All other authors declared no conflict of interest.
Graph: Aspergillus lateral flow device ( LFD ) qualitative results were interpreted as a ‘positive’ if both the test (T) and the control (C) line were present or ‘negative’ if only red line appeared in the control (C) zone. (a) Positive LFD test result. (b) Negative LFD test.
Graph: Patients Breakdown. BAL: bronchoalveolar; IA: invasive aspergillosis; N: number of patients.
By Marisa H. Miceli; Michael I. Goggins; Pranay Chander; Archana K. Sekaran; Anne E. Kizy; Linoj Samuel; Hui Jiang; Christopher R. Thornton; Mayur Ramesh and George Alangaden